Cambridge, UK, and Stockholm, Sweden, 03 December 2019: Horizon Discovery Group plc (LSE: HZD) (“Horizon”), a global leader in the application of gene editing and gene modulation for cell line engineering, today announced that it has entered into a partnership with The Human Protein Atlas (HPA). HPA has selected Horizon’s CRISPR-edited knockout cell models to further expand the knowledge available in its Cell Atlas program, to advance our understanding of the genetic drivers of disease. Knockout cell models offer the possibility for an enhanced validation of antibodies based on genetic…
Cambridge, UK, 03 December 2019: IONTAS Limited (IONTAS), a leader in the discovery and optimisation of fully human antibodies, today announced it has entered into a collaboration agreement with Adaptate Biotherapeutics, developers of antibody-based therapeutics for modulation of gamma delta T-cells. The agreement is to generate and optimise antibodies for novel immuno-oncology targets, including access to IONTAS’ proprietary Mammalian Display technology to select antibodies with optimal biophysical properties.
IONTAS’ proprietary technology enables the construction of large libraries of…
Cambridge and London, UK, 03 December 2019: Metrion Biosciences Limited (Metrion), the specialist ion channel CRO and drug discovery company, and LifeArc, a leading UK independent medical research charity, today announced an extension of their neuroscience-focused ion channel drug discovery collaboration, following the success of the initial twelve-month agreement.
The collaboration is focused on novel selective small molecular modulators of a specific two-pore domain potassium ion channel target, identified as likely to be involved in neurological pathogenesis. Having commenced in January…
Cambridge, UK: Global courier for cell and gene therapy, Biocair, will exhibit at Cell Therapy Manufacturing and Gene Therapy Congress between 3-6 December 2019. Taking place in Amsterdam, Cell Therapy Manufacturing and Gene Therapy Congress brings together key players from the industry to discuss the critical issues facing the development, scale-up and manufacture of cell-based and gene therapies.
Speaking about the logistics surrounding cell and gene therapy, Gert de Gier, Cell and Gene Business Development Director at Biocair, comments that “with cell and gene therapies moving into the…
NEW STATE-OF-THE-ART FACILITY DRAMATICALLY INCREASES CAPACITY FOR CLINICAL TRIALS AND OFFERS CLIENTS FIRST-OF-ITS-KIND CELL PROFILING CAPABILITIES COMBINING EPIGENETICS AND FLOW CYTOMETRY
BERLIN, GERMANY – 27 NOVEMBER 2019 – Precision for Medicine, part of Precision Medicine Group, today announced that they have opened a new 1,600 metre-squared Berlin-based laboratory, for the first time combining its proprietary Epiontis ID™ epigenetic immune-monitoring technology with advanced flow cytometry capabilities, along with a full-service biorepository and cell processing laboratory. Focusing on…
London, UK, 28th November 2019 One Nucleus reveals the finalists of its annual BioNewsRound Award, recognising life science companies that have announced exciting developments for patients and the sector. The finalists will present at Genesis 2019 where the winner will be announced.
Companies were nominated for their most important news stories from the last year. These were assessed based on their impact on the organisation, whether they demonstrated an exciting development in the life sciences sector and whether they have the potential to significantly benefit…
AMSBIO reports on how it has worked with Singapore General Hospital (Singapore) to help them identify the best reagent to transfect their human embryonic stems cells.Historically the research group of Prof Tan Eng-King had used GeneIN, a transfection reagent specifically developed for stem cells which is now no longer available. Working with AMSBIO, Singapore General Hospital tested several reagents before electing to switch to GenePORTER® 2 to efficiently transfect their human embryonic stem cells. Senior researcher - Dr Christine Chan Hui Shan commented “Human embryonic stem cells…
Hertfordshire Local Enterprise Partnership is to invest £1.2m into Stevenage Bioscience Catalyst (SBC) to help grow a world-class cell and gene therapy cluster.
The £1.2m Local Growth Fund investment will provide much-needed temporary accommodation for growing cell and gene therapy companies, strengthening the UK’s sectorial advantage and Hertfordshire’s position within the Oxford-London-Cambridge golden research triangle.
SBC is a world-leading science park of global significance and home to the largest cluster of cell and gene therapy companies in Europe. Since its opening in 2012, it has…
Cambridge, UK, 19 November 2019: Chesterford Research Park and Microbiotica, a leading player in microbiome-based therapeutics and biomarkers, announce that Microbiotica is relocating to the Park in a two-phase move that will be completed in June 2020.
Microbiotica’s continuing development and expansion, and the ability of Chesterford Research Park to flexibly accommodate both Microbiotica’s immediate and longer-term growth requirements led to the Park being chosen as the preferred location.
Under the first phase of the relocation, Microbiotica is taking two suites within Chesterford Research…